Shelf life (days): 1460.0
Formulation: A solid
Formal Name: (R)-N-(methyl-d3)-3-phenyl-3-(o-tolyloxy)propan-1-amine, monohydrochloride
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C17H18D3NO / HCl
Formula Weight: 294.8336
CAS Number: 1217776-38-9
Notes: Atomoxetine-d3 is intended for use as an internal standard for the quantification of atomoxetine (Item No. 22248) by GC- or LC-MS. Atomoxetine is a selective norepinephrine reuptake inhibitor with Ki values of 5, 77, and 1,451 nM for norepinephrine, serotonin, and dopamine transporters, respectively.{38422} It is selective over the choline, GABA, and adenosine transporters, and a number of neurotransmitter receptors, ion channels, second messengers, and brain/gut peptides. In the rat prefrontal cortex (PFC), it increases extracellular norepinephrine and dopamine by 3-fold and increases Fos expression. Atomoxetine (0.1, 0.5, and 1 mg/kg) reduces premature responding, a measure of impulsivity, by rats in the 5-choice serial reaction time test (5CRTT) in a dose-dependent manner.{38421} It also has neuroprotective effects when administered prior to ischemic damage in a gerbil model of transient cerebral ischemia.{38423} Formulations containing atomoxetine have been used in the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults.
Deutsch
English
